NRF2 gene therapy (CorriXR Therapeutics)

N/A

Report date: 2025/01/26 16:45:15

Base Information

Drug NameNRF2 gene therapy (CorriXR Therapeutics)
Drug Alias NameCRISPR/Cas9 gene editing therapy (Christiana)NRF2 gene therapy (Christiana Care Health Services/University of Delaware)
ClassificationBiologics
Mechanisms of ActionNuclear factor erythroid 2-related factor 2 inhibitors
TargetsNuclear factor erythroid 2-related factor 2
Therapy Area/IndicationsLung NeoplasmsCarcinoma, Squamous CellNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesChristiana Care Health Services Inc
China Registration ClassN/A

Develop Information

Active CompaniesCorriXR Therapeutics Corp
Inactive CompaniesChristiana Care Health Services Inc
Active IndicationsLung NeoplasmsCarcinoma, Squamous Cell
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A